|
Market Closed -
Nasdaq
16:00:00 2026-10-16 EDT
|
5-day change | 1st Jan Change | ||
| 113.07 USD | -0.18% |
|
+0.25% | +14.48% |
| 10-15 | Goldman Sachs Adjusts Price Target on Incyte to $117 From $118 | MT |
| 10-14 | Truist Raises Price Target on Incyte to $115 From $105, Keeps Hold Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 22.92B | |||||
| 1,120B | |||||
| 616B | |||||
| 504B | |||||
| 367B | |||||
| 360B |
- Stock Market
- Stocks
- INCY Stock
- Charts Incyte Corporation
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
